Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Common Equity (2018 - 2026)

Profound Medical has reported Common Equity over the past 8 years, most recently at $66.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 9.95% year-over-year to $66.4 million; the TTM value through Dec 2025 reached $66.4 million, up 9.95%, while the annual FY2025 figure was $66.4 million, 9.95% up from the prior year.
  • Common Equity for Q4 2025 was $66.4 million at Profound Medical, up from $32.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $80.6 million in Q4 2021 and troughed at $30.7 million in Q3 2024.
  • A 5-year average of $48.1 million and a median of $45.5 million in 2024 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 40.64% in 2023 and later soared 93.51% in 2024.
  • Year by year, Common Equity stood at $80.6 million in 2021, then crashed by 34.76% to $52.6 million in 2022, then crashed by 40.64% to $31.2 million in 2023, then soared by 93.51% to $60.4 million in 2024, then rose by 9.95% to $66.4 million in 2025.
  • Business Quant data shows Common Equity for PROF at $66.4 million in Q4 2025, $32.1 million in Q3 2025, and $39.3 million in Q2 2025.